Agoracom: Small Cap Investment - Zenith Epigenetics - Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Nextblockbuster

Rank: President [?]

Points: 2717 [?]

Votes: 15 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

in response to

Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

LongRVXer

posted on Feb 22, 2022 10:24AM

Long, I agree that they seems Zenith/RVX like BMS would be great fit to their Portfolio, that being said RVX/Zenith woudl be a great fir for any BP. If Epigenetics is the next CRISPR for novel /futuristic medicine than one of the BP should take a gamble at a buyout or large Partnership with both co's

Constellation Phara has alrady been taken out, so you would think another BP would be interested in both Zenith and RVX , Just has to be at the right price. That could be the disconnect

6 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply